ClinicalTrials.gg

Program

paliroden

Also written as “SR57667B”, “CIL001 (Paliroden)” and “paliroden (CIL001)”.

Its studies are mostly in Parkinson Disease · Alzheimer Disease · Diabetes Mellitus · Tinnitus, led by 2 companies.

Furthest: phase 2, since Sep 16, 20056 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi40 open or runningphase 2since Sep 16, 2005Sep 16, 2005none ahead
Cilcare SAS22 open or runningphase 2since Feb 24, 2026Feb 24, 2026Dec 2027phase 2 · NCT07472907

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 16, 2005First studies: 2 phase 2 studies in Parkinson DiseaseNew to SanofiSanofi · NCT00220272, NCT00228150
  2. Jan 31, 20062 phase 2 studies in Alzheimer DiseaseSanofi · NCT00285077, NCT00285025
  3. Feb 24, 2026Cilcare SAS's first study: phase 2 study in Hearing Loss, HiddenNew to Cilcare SASCilcare SAS · NCT07472907 · 135 planned
  4. Sep 4, 2026Phase 2 study in TinnitusCilcare SAS · NCT07826507 · 60 planned

Ahead

  1. Dec 2027Primary completion: phase 2 study in Hearing Loss, HiddenCilcare SAS · NCT07472907
  2. Jan 2028Primary completion: phase 2 study in TinnitusCilcare SAS · NCT07826507

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07826507Tinnitus2Not yet recruitingCilcare SASJan 202860
NCT07472907Hearing Loss, Hidden2Not yet recruitingCilcare SASDec 2027135
NCT00285077Alzheimer Disease · Canada, Denmark, Finland and more2CompletedSanofiNov 2006390
NCT00285025Alzheimer Disease2CompletedSanofi500
NCT00228150Parkinson Disease · Austria, Canada, Denmark and more2CompletedSanofiApr 2006564
NCT00220272Parkinson Disease · Canada, Finland, France and more2CompletedSanofiMar 2007183

How it is read

Names in the registry

  • “SR57667B”, 4 entries
  • “CIL001 (Paliroden)”, 1 entry
  • “paliroden (CIL001)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.